In KRAS WT CRC, high expression of AREG and EREG messenger RNA (mRNA) is predictive of improved response rate, progression-free survival and overall survival in patients treated with cetuximab [42–44]. The gene discussed is KRAS; the disease is colorectal carcinoma.